(C) World Health Organization This story was originally published by World Health Organization and is unaltered. . . . . . . . . . . Private sector dialogue on cervical cancer elimination: Strengthening concerted action to achieve the 2030 targets for cervical cancer elimination through expanding access to products and services for [1] [] Date: 2024-06-25 Background Cervical cancer is preventable and curable if it is detected early and managed effectively. However, it is the fourth most common form of cancer among women worldwide, with approximately 662 000 women diagnosed annually. Cervical cancer also claimed the lives of almost 350 000 women in 2022 with over 90% of those deaths occurring in low- and middle-income countries. In 2020 Member States adopted the Global strategy to accelerate the elimination of cervical cancer as a public health problem. WHO is convening biannual dialogues with private sector entities, including representatives from international business associations, and the pharmaceutical and health technology industry. The dialogues focus on ensuring commitments and contributions by the private sector entities toward the noncommunicable diseases (NCDs) response on NCDs to achieve sustainable development goal targets 3.4, 3.8, and 3.b. The objectives of the meeting are to: provide an overview of progress across the 3 pillars of the Global strategy to accelerate the elimination of cervical cancer as a public health problem; provide an update on WHO’s work and current approaches to support countries to implement and scale secondary prevention services; broaden understanding of persistent barriers, implementation challenges, and opportunities that can be leveraged within the context of low-resource settings; strengthen the collaboration between WHO, intergovernmental agencies, and non-State actors in accordance with WHO’s rules and policies including the Framework of engagement with non-State actors (FENSA) in a meaningful way towards the development of commitments and contributions by the relevant private sector entities (including manufacturers of molecular in vitro diagnostic products); share views on the preliminary set of WHO asks for private sector entities, including pharmaceutical and health technology manufacturers; discuss potential opportunities for concerted action to expand access to tools, innovations, and services for secondary prevention of cervical cancer. Expected outcome A final report on identified challenges, potential approaches for expanding access to diagnostic tools for secondary prevention, and preliminary WHO asks for the pharmaceutical and health technology industry to strengthen commitments and contributions toward the implementation and scale-up of screening and treatment services within countries. Format A 2-day virtual participation via the Zoom videoconference platform. Date and time: 25 and 26 June 2024, 14:00–17:00 CEST Participants Selected Member States, private sector entities, partners, international procurers, purchasers, and/or funders of procurement for cervical cancer prevention and control technologies. Language The working language of the meeting will be English. For more information please contact Bashier Enoos (enoosb@who.int). [END] --- [1] Url: https://www.who.int/news-room/events/detail/2024/06/25/default-calendar/private-sector-dialogue-on-cervical-cancer-elimination-strengthening-concerted-action-to-achieve-the-2030-targets-for-cervical-cancer-elimination-through-expanding-access-to-products-and-services-for-secondary-prevention Published and (C) by World Health Organization Content appears here under this condition or license: Creative Commons CC-BY-NC-SA 3.0 IGO. via Magical.Fish Gopher News Feeds: gopher://magical.fish/1/feeds/news/who/